Form 4: BioLife Solutions Executive Sells Shares to Cover Tax Obligations
Insider Transaction Disclosure
Karen A. Foster, Chief Quality and Operations at BioLife Solutions Inc., sold 320 shares of common stock for tax withholding purposes, as disclosed in a recent SEC Form 4 filing.
Summary
- Karen A. Foster, the Chief Quality and Operations Officer of BioLife Solutions Inc. (BLFS), reported the sale of 320 shares of the company's common stock.
- The transaction occurred on June 10, 2025, with shares sold at a price of $23.7 per share.
- This sale was executed under a Rule 10b5-1(c) trading plan, which was adopted by Ms. Foster on March 8, 2024.
- The primary purpose of the sale was to satisfy tax withholding obligations related to the vesting of restricted stock.
- Following this transaction, Ms. Foster beneficially owns 194,996 shares of BioLife Solutions common stock.
Sentiment
Score: 5
Explanation: The sentiment is neutral. The transaction is a routine, non-discretionary sale by an insider to cover tax liabilities associated with equity compensation, not indicative of a change in sentiment towards the company or its prospects.
Future Outlook
N/A
Management Comments
- The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 03-08-2024 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.
Industry Context
This type of transaction, where an executive sells shares to cover tax obligations arising from equity compensation, is a common and routine event across publicly traded companies in various industries, including the life sciences sector where BioLife Solutions operates.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Trading Plan Adoption | The sale was made pursuant to a Rule 10b5-1(c) trading plan, which allows insiders to set up pre-scheduled trades to avoid accusations of trading on material non-public information. This demonstrates adherence to corporate governance best practices regarding insider trading. | 03-08-2024 | Enhances transparency and reduces potential for insider trading concerns by pre-arranging transactions. |
Stakeholder Impact
- Shareholders: The sale of a small number of shares for tax purposes by an executive is unlikely to have a significant impact on the company's stock price or investor sentiment, as it is a routine administrative transaction.
Key Dates
| Date | Description |
|---|---|
| 03-08-2024 | Date the Rule 10b5-1(c) trading plan was adopted by Karen A. Foster. |
| 06/10/2025 | Date of the reported transaction (sale of common stock). |
| 06/12/2025 | Date the Form 4 was signed by Karen A. Foster. |
Keywords
BioLife Solutions, BLFS, SEC Form 4, Insider Trading, Stock Sale, Rule 10b5-1, Tax Withholding, Restricted Stock, Executive Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.